AU2001236720A1 - Compositions useful as inhibitors of erk - Google Patents
Compositions useful as inhibitors of erkInfo
- Publication number
- AU2001236720A1 AU2001236720A1 AU2001236720A AU3672001A AU2001236720A1 AU 2001236720 A1 AU2001236720 A1 AU 2001236720A1 AU 2001236720 A AU2001236720 A AU 2001236720A AU 3672001 A AU3672001 A AU 3672001A AU 2001236720 A1 AU2001236720 A1 AU 2001236720A1
- Authority
- AU
- Australia
- Prior art keywords
- erk
- inhibitors
- compositions useful
- compositions
- useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18050200P | 2000-02-05 | 2000-02-05 | |
US60180502 | 2000-02-05 | ||
US19195900P | 2000-03-24 | 2000-03-24 | |
US60191959 | 2000-03-24 | ||
PCT/US2001/003904 WO2001056557A2 (en) | 2000-02-05 | 2001-02-05 | Compositions useful as inhibitors of erk |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001236720A1 true AU2001236720A1 (en) | 2001-08-14 |
Family
ID=26876382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001236720A Abandoned AU2001236720A1 (en) | 2000-02-05 | 2001-02-05 | Compositions useful as inhibitors of erk |
Country Status (5)
Country | Link |
---|---|
US (2) | US6849267B2 (en) |
EP (1) | EP1207864A2 (en) |
AU (1) | AU2001236720A1 (en) |
CA (1) | CA2369502A1 (en) |
WO (1) | WO2001056557A2 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6436915B1 (en) | 2000-04-07 | 2002-08-20 | Kinetek Pharmaceuticals, Inc. | Pyrazole compounds |
JP4052573B2 (en) | 2000-09-15 | 2008-02-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | Isoxazole and its use as an inhibitor of ERK |
JP2005519878A (en) | 2001-11-30 | 2005-07-07 | キネテク ファーマシューティカルズ,インコーポレーテッド | Hydrazonopyrazole derivatives and their use as therapeutic agents |
US20040175384A1 (en) * | 2003-12-12 | 2004-09-09 | Mohapatra Shyam S. | Protein kinase C as a target for the treatment of respiratory syncytial virus |
DE602004012578T2 (en) | 2003-08-15 | 2008-12-11 | Vertex Pharmaceuticals Inc., Cambridge | PYROME COMPOSITIONS SUITED AS INHIBITORS OF C-MET |
MXPA06004827A (en) * | 2003-10-31 | 2006-07-03 | Procter & Gamble | Method of providing a blended composition. |
US8592368B2 (en) * | 2003-12-19 | 2013-11-26 | University Of South Florida | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
SE526596C2 (en) | 2004-01-13 | 2005-10-11 | Vaelinge Innovation Ab | Floating floor with mechanical locking system that allows movement between the floorboards |
TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
CA2642762A1 (en) | 2006-02-16 | 2007-08-30 | Schering Corporation | Pyrrolidine derivatives as erk inhibitors |
UY30892A1 (en) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | AKT ACTIVITY INHIBITORS |
WO2008138123A1 (en) * | 2007-05-09 | 2008-11-20 | Thomas David Y | Screening assay to identify correctors of protein trafficking defects |
JP5276676B2 (en) | 2008-02-21 | 2013-08-28 | メルク・シャープ・アンド・ドーム・コーポレーション | Compounds that are ERK inhibitors |
WO2010028236A1 (en) * | 2008-09-05 | 2010-03-11 | Avila Therapeutics, Inc. | Algorithm for designing irreversible inhibitors |
KR20120093220A (en) * | 2009-09-16 | 2012-08-22 | 아빌라 테라퓨틱스, 인크. | Protein kinase conjugates and inhibitors |
CN102812167A (en) | 2009-12-30 | 2012-12-05 | 阿维拉制药公司 | Ligand-directed Covalent Modification Of Protein |
KR101151715B1 (en) * | 2010-01-21 | 2012-06-15 | 중앙대학교 산학협력단 | Method for Diagnosis of Prostatitis and Kit for the Same |
ES2575995T3 (en) | 2010-08-05 | 2016-07-04 | Case Western Reserve University | ERK inhibitors for developmental disorders of neuronal connectivity |
WO2012160130A1 (en) | 2011-05-25 | 2012-11-29 | Universite Paris Descartes | Erk inhibitors for use in treating spinal muscular atrophy |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
EP3355923B1 (en) | 2015-10-01 | 2022-02-23 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma |
WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
TW202102511A (en) | 2019-03-28 | 2021-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | A thienyl fused heterocyclic derivative, a preparation method thereof, and medical applications thereof |
JP2022528083A (en) | 2019-03-29 | 2022-06-08 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Pyrrolo heterocyclic derivative, preparation method for this derivative and its use in medicine |
JP2022534224A (en) | 2019-05-24 | 2022-07-28 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Substituted Fused Bicyclic Derivatives, Methods for Their Preparation, and Their Applications in Medicine |
US20230331731A1 (en) | 2020-09-29 | 2023-10-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystal form of pyrrolo heterocyclic derivative and preparation method therefor |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9608435D0 (en) * | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
JP2002502379A (en) * | 1997-05-22 | 2002-01-22 | ジー.ディー.サール アンド カンパニー | 3 (5) -heteroaryl-substituted pyrazoles as p38 kinase inhibitors |
AU7726898A (en) * | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
GB9721437D0 (en) * | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
IL145756A0 (en) * | 2000-02-05 | 2002-07-25 | Vertex Pharma | Pyrazole derivatives and pharmaceutical compositions containing the same |
CA2445568A1 (en) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
-
2001
- 2001-02-05 AU AU2001236720A patent/AU2001236720A1/en not_active Abandoned
- 2001-02-05 CA CA002369502A patent/CA2369502A1/en not_active Abandoned
- 2001-02-05 EP EP01908908A patent/EP1207864A2/en not_active Withdrawn
- 2001-02-05 WO PCT/US2001/003904 patent/WO2001056557A2/en not_active Application Discontinuation
- 2001-10-05 US US09/971,533 patent/US6849267B2/en not_active Expired - Fee Related
-
2003
- 2003-05-13 US US10/437,419 patent/US6994868B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20030049820A1 (en) | 2003-03-13 |
US20040048861A1 (en) | 2004-03-11 |
US6994868B2 (en) | 2006-02-07 |
WO2001056557A3 (en) | 2002-04-04 |
EP1207864A2 (en) | 2002-05-29 |
US6849267B2 (en) | 2005-02-01 |
WO2001056557A2 (en) | 2001-08-09 |
CA2369502A1 (en) | 2001-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001236720A1 (en) | Compositions useful as inhibitors of erk | |
HUP0202332A2 (en) | Pyrazole compositions useful as inhibitors of erk | |
AU2003286711A1 (en) | Indazolinone compositions useful as kinase inhibitors | |
AU2001258771A1 (en) | -secretase inhibitors | |
AU2002219418A1 (en) | Compositions of estrogen-cyclodextrin complexes | |
AU2002220265A1 (en) | Compositions for inhibiting grb7 | |
AU2001244399A1 (en) | Gamma-secretase inhibitors | |
HK1039110A1 (en) | Novel compounds and compositions as protease inhibitors | |
AU2001253255A1 (en) | Compositions and methods for inhibiting gene expression | |
AU2001245764A1 (en) | Novel compounds and compositions as protease inhibitors | |
AU1530001A (en) | Inhibitor compositions | |
AU2002317374A1 (en) | Storage of liquid compositions | |
AU6381701A (en) | Bisamidino compounds as nhe-3 inhibitors | |
AU2002256543A1 (en) | Compositions containing heteropolymers and methods of using same | |
AU2001270200A1 (en) | Fatty acid synthase inhibitors | |
AU2001296515A1 (en) | Cyclic sulfonyl compounds as inhibitors of metalloproteases | |
AU2002304853A1 (en) | Substituted benzopyranones as telomerase inhibitors | |
AU2001280721A1 (en) | Compositions of iodonium compounds and methods and uses thereof | |
AU2001281059A1 (en) | Fatty acid synthase inhibitors | |
AU2002241211A1 (en) | Imidazo-triazine derivatives as pde 5 inhibitors | |
AU2001255408A1 (en) | Tetrahydro-azepinone derivatives as thrombin inhibitors | |
AU2002214038A1 (en) | Inhibitors of transglutaminases | |
AU2001271531A1 (en) | Fatty acid synthase inhibitors | |
AUPQ644900A0 (en) | Preserving compositions | |
AU2001274940A1 (en) | Fatty acid synthase inhibitors |